The head of the Pasteur Institute of Iran emphasized that the safety and efficacy of the Pastocovac vaccine has been proven.

 
"The vaccine has been shown to be effective and  safe against COVID-19," Biglari said.
 
The head of the Pasteur Institute of Iran (IPI) also said: "The article obtained from the results of the study of the third phase of the Pastecovac vaccine trial in Iran has been accepted in a journal with very high scientific and international prestige and will be published soon."
 
Pastecovac is a recombinant vaccine. The first and second phases of the clinical trial of this vaccine were co-produced by the Cuban Finlay Institute and the Pasteur Institute of Iran in Cuba.
 
In the first phase, 40 volunteers, and in the second phase, 920 volunteers were present. In these two phases, the safety of the vaccine and determining the appropriate dose were evaluated.
 
The third phase of the clinical trial of this vaccine was performed in Iran and Cuba with 44,000 volunteers in Cuba and 24,000 volunteers in Iran.
 
Pastecovac Plus have received an emergency use license from the Food and Drug Administration of Iran.